AXON Neuroscience - Articles and news items

AXON Neuroscience’s vaccine designed to halt Alzheimer’s finishes Phase 1 clinical trial

Industry news / 8 July 2015 / Victoria White

AXON Neuronscience’s vaccine intended to be a disease modifying drug for Alzheimer’s disease patients has passed a Phase 1 safety trial…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+